Verve is focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary artery disease, the most common type of heart disease and the leading cause of death worldwide.
Verve brings together two of the biggest breakthroughs in 21st century biomedicine — human genetic analysis and gene editing — to realize a new future, one of longevity and vitality for tens of millions of people worldwide at risk of coronary artery disease.
Verve has been purpose-built for the task ahead, with a founding team of world-leading experts in cardiovascular medicine and patient care, cardiovascular genetics, gene editing delivery technology and safety, drug development, and company-building.
Collaborations and Licensing
Verve has established foundational collaborations with industry leaders in gene editing and delivery technologies, including Beam Therapeutics and Verily. The company also has in-licensed technology from the Broad Institute and Harvard University.